Joshua M. Eizen's most recent trade in AN2 Therapeutics Inc was a trade of 117,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AN2 Therapeutics Inc | Joshua M. Eizen | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 117,000 | 117,000 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Joshua M. Eizen | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 58,500 | 175,172 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Joshua M. Eizen | See Remarks | Sale of securities on an exchange or to another person at price $ 1.34 per share. | 03 Jan 2025 | 9,663 | 116,672 | - | 1.3 | 12,958 | Common Stock |
| AN2 Therapeutics Inc | Joshua M. Eizen | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2024 | 63,000 | 63,000 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Joshua M. Eizen | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2024 | 31,500 | 126,335 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Joshua M. Eizen | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2024 | 60,000 | 94,833 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Joshua M. Eizen | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Joshua M. Eizen | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 30,000 | 32,447 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Joshua M. Eizen | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 30,000 | 32,447 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Joshua M. Eizen | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 50,150 | 50,150 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Joshua M. Eizen | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Oct 2022 | 92,000 | 92,000 | - | - | Stock Option (right to buy) |